Xi'an Xintong 1.1 liver cancer targeting new drug "mb07133 for injection" obtained clinical approval

Recently, with the approval of the State Food and drug administration, the new drug mb07133 for injection, a class 1.1 liver cancer targeting drug declared by Xi'an Xintong Pharmaceutical Research Co., Ltd., has been approved for clinical research, marking a major breakthrough in the research of new drugs targeting liver cancer in China It is reported that mb07133 is a prodrug of cytarabine The results of phase I clinical trials in the United States, Hong Kong and Taiwan showed that the average survival time of patients with advanced liver cancer was 9.7 months, 30% of them had a longer survival time, up to 14.9 months, while the current leading drug for liver cancer, the German Bayer company, produced solafeni, was 6.5 months It is estimated that after mb07133 goes on the market, the daily cost of medicine will be 500 yuan, which will greatly reduce the burden of patients while satisfying the clinical medication.